Christian Migliarese,Hiroaki Wakimoto
Christian Migliarese
Radiovirotherapy at twenty [0.03%]
放疗与靶向治疗二十年
David Dingli
David Dingli
Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy [0.03%]
嵌合抗原受体t细胞疗法联合溶瘤病毒治疗的机遇与挑战
Joseph A Mamola,Chun-Yu Chen,Mark A Currier et al.
Joseph A Mamola et al.
The use of oncolytic viruses (OVs) and adoptive cell therapies (ACT) have independently emerged as promising approaches for cancer immunotherapy. More recently, the combination of such agents to obtain a synergistic anticancer effect has ga...
Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor [0.03%]
基于工程化下游转录因子调控的CD19 CAR-T细胞活化研究
Duško Lainšček,Anja Golob-Urbanc,Veronika Mikolič et al.
Duško Lainšček et al.
CAR-T cells present a highly effective therapeutic option for several malignant diseases, based on their ability to recognize the selected tumor surface marker in an MHC-independent manner. This triggers cell activation and cytokine product...
Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity [0.03%]
武装有降解细菌GBP1的溶瘤单纯疱疹病毒提高抗肿瘤活性
Jun Xie,Shaowei Wang,Yunhong Zhong et al.
Jun Xie et al.
Oncolytic viruses (OVs) encoding various transgenes are being evaluated for cancer immunotherapy. Diverse factors such as cytokines, immune checkpoint inhibitors, tumor-associated antigens, and T cell engagers have been exploited as transge...
Zhiyuan Mao,John K Lee
Zhiyuan Mao
New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer [0.03%]
前列腺癌综合靶向治疗和免疫治疗的作用机制及效应的新认知和选择
Mingen Lin,Xue Sun,Lei Lv
Mingen Lin
Chronic inflammation is believed to drive prostate carcinogenesis by producing reactive oxygen species or reactive nitrogen species to induce DNA damage. This effect might subsequently cause epigenetic and genomic alterations, leading to ma...
Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T [0.03%]
CAR-T持久性相关的难治/复发B-细胞急性淋巴细胞白血病的持久缓解以及首剂CAR-T的长期持久性潜力
Li Shiqi,Zhang Jiasi,Chen Lvzhe et al.
Li Shiqi et al.
CD19-targeted chimeric antigen receptor T lymphocytes (CAR-T) has demonstrated a high proportion of complete remission in the treatment of relapsed refractory acute B cell lymphoblastic leukemia (r/r B-ALL). It is of great clinical signific...
Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis [0.03%]
天花病毒和肽受体放射性治疗协同改善腹膜癌瘤的治疗效果
Kathryn Ottolino-Perry,David Mealiea,Clara Sellers et al.
Kathryn Ottolino-Perry et al.
Tumor-specific overexpression of receptors enables a variety of targeted cancer therapies, exemplified by peptide-receptor radiotherapy (PRRT) for somatostatin receptor (SSTR)-positive neuroendocrine tumors. While effective, PRRT is restric...